The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 3 (PCV3) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV3 infection.

This invention relates generally to compositions for making anellovectors and uses thereof.

A PCV2 vaccine and a method of vaccinating against PCV2 are provided herein. The PCV2 vaccine includes a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof, wherein the re-engineered PCV2 capsid includes a modified immunogenic region. The method of vaccinating against PCV2 includes administering the PCV2 vaccine including a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof to a subject in need thereof.

Vaccines of preferential administration via mucous membranes, for the control of viral diseases generated by infectious agents that use heparan sulfate (HS) as a cellular receptor consisting of an immunogenic formulation for veterinary use, comprising an antigen whose cellular receptor is heparan sulfate (HS), a vehicle for oral, intranasal or parenteral administration, wherein said vehicle corresponds to D-glucosamine and functionalized N-acetyl-D-glucosamine biopolymers, with sulfur atoms, and/or functionalized chitosan biopolymer, with sulfur atoms, and where the antigen is microencapsulated by said types of functionalized biopolymers.

Provided herein is a mammalian expression system for producing recombinant porcine circovirus type 2 (PCV2) virus-like particles (VLPs). The expression system includes a mammalian cell and a plasmid that comprises a PCV2 gene encoding a capsid protein. The PCV2 gene is codon optimized, and the mammalian cell is transfected with the plasmid. The expression system produces recombinant PCV2 VLPs, such as PCV2d VLPs. Also provided herein are a method for producing porcine circovirus type 2 (PCV2) virus-like particles (VLPs), as well as a PCV2 VLP generated by the method.

The present invention relates to recombinantly constructed polypeptides useful for preparing vaccines, in particular for reducing one or more clinical signs caused by an infection with at least one pathogen, such as clinical signs caused by a viral infection. More particular, the present invention is directed to a polypeptide comprising a Circoviridae capsid protein linked to a heterologous protein or fragment thereof, and to chimeric virus-like particles composed of such polypeptides. In one example, a fusion protein is provided which comprises PCV2 ORF2 protein linked to an immunogenic fragment of rotavirus VP8 protein, and which is usable for reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

Provided is PCV2 VLP that can be used as a vaccine for use in the field of animal husbandry and that has high molecular stability against physicochemical load. A fusion protein according to the present invention includes a capsid protein of porcine circovirus type 2 and an immunoglobulin-binding domain.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.